Klinikum rechts der Isar der TU Muenchen

München 81675

2 studies enrolling now · 6 studies all time

What they study most

Gastric Cancer, Gastroesophageal Junction Cancer, Metastatic Castration-resistant Prostate Neoplasms, Multiple Myeloma, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Solid Tumors

Studies at this site

• A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) — Recruiting now
• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis — Recruiting now
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis — Running, not enrolling
• Screening Study for Participants With Malignant Tumors — Completed